328 related articles for article (PubMed ID: 27790726)
1. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
[TBL] [Abstract][Full Text] [Related]
2. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects.
Shin D; Kim Y; Go A; Velinova M
Drug Des Devel Ther; 2020; 14():43-50. PubMed ID: 32021090
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.
Lee YJ; Shin D; Kim Y; Kang J; Gauliard A; Fuhr R
Br J Clin Pharmacol; 2016 Jul; 82(1):64-73. PubMed ID: 26972584
[TBL] [Abstract][Full Text] [Related]
6. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
Bush J; Kawakami K; Muniz R
BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
[TBL] [Abstract][Full Text] [Related]
7. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
[TBL] [Abstract][Full Text] [Related]
8. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
[No Abstract] [Full Text] [Related]
9. Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis.
Rho YH; Rychlewska-Hańczewska A; Śliwowska B; Kim TH
Adv Ther; 2019 Sep; 36(9):2287-2295. PubMed ID: 31372961
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
Shin D; Lee Y; Jeong D; Ellis-Pegler R
Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
12. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
[TBL] [Abstract][Full Text] [Related]
14. An Open-Label, Randomized, Single-Dose, Crossover, Comparative Pharmacokinetics Study of YLB113 and the Etanercept Reference Product in Healthy Adult Male Subjects.
Shennak M; Al-Jaouni R; Kshirasagar S; Kasibhatta RS; Godse N; Al-Ghazawi A; Vittala P; Bakhle D
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):467-475. PubMed ID: 32172488
[TBL] [Abstract][Full Text] [Related]
15. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
16. LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects.
Lee H; Chung H; Lee S; Lee H; Yang SM; Yoon SH; Cho JY; Jang IJ; Yu KS
BioDrugs; 2017 Aug; 31(4):349-355. PubMed ID: 28551775
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Sangana R; Xu Y; Shah B; Tian X; Zack J; Shakeri-Nejad K; Kalluri S; Jones I; Ligueros-Saylan M; Taylor AF; Jain DK; Scosyrev E; Uddin A; Laurent N; Paganoni P
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):611-620. PubMed ID: 38389387
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.
Matucci-Cerinic M; Allanore Y; Kavanaugh A; Buch MH; Schulze-Koops H; Kucharz EJ; Woehling H; Babic G; Poetzl J; Davis A; Schwebig A
RMD Open; 2018; 4(2):e000757. PubMed ID: 30487998
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]